{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T12:02:29Z","timestamp":1778500949384,"version":"3.51.4"},"reference-count":219,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Platelets play an important role in hemostasis, and a low platelet count usually increases the risk of bleeding. Conditions in which thrombosis occurs despite low platelet counts are referred to as thrombosis with thrombocytopenia syndrome, including heparin-induced thrombocytopenia, vaccine-induced immune thrombotic thrombocytopenia, paroxysmal nocturnal hemoglobinuria, antiphospholipid syndrome, thrombotic microangiopathy (TMA), and disseminated intravascular coagulation. TMA includes thrombotic thrombocytopenic purpura, Shiga toxin-producing Escherichia coli-associated hemolytic uremic syndrome (HUS), and atypical HUS. Patients with these pathologies present with thrombosis and consumptive thrombocytopenia associated with the activation of platelets and the coagulation system. Treatment varies from disease to disease, and many diseases have direct impacts on mortality and organ prognosis if therapeutic interventions are not promptly implemented. Underlying diseases and the results of physical examinations and general laboratory tests as part of a thorough workup for patients should promptly lead to therapeutic intervention before definitive diagnosis. For some diseases, the diagnosis and initial treatment must proceed in parallel. Utilization of not only laboratory tests but also various scoring systems is important for validating therapeutic interventions based on clinical information.<\/jats:p>","DOI":"10.3390\/ijms25094956","type":"journal-article","created":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T08:59:39Z","timestamp":1714553979000},"page":"4956","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["How We Interpret Thrombosis with Thrombocytopenia Syndrome?"],"prefix":"10.3390","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7415-2918","authenticated-orcid":false,"given":"Shinya","family":"Yamada","sequence":"first","affiliation":[{"name":"Department of Hematology, Kanazawa University Hospital, Takaramachi 13-1, Kanazawa City 920-8640, Ishikawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1834-1690","authenticated-orcid":false,"given":"Hidesaku","family":"Asakura","sequence":"additional","affiliation":[{"name":"Department of Hematology, Kanazawa University Hospital, Takaramachi 13-1, Kanazawa City 920-8640, Ishikawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,5,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1182\/blood.V97.9.2549","article-title":"Morbidity and mortality in adults with idiopathic thrombocytopenic purpura","volume":"97","author":"Portielje","year":"2001","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1001\/archinte.160.11.1630","article-title":"The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts","volume":"160","author":"Cohen","year":"2000","journal-title":"Arch. Intern. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1182\/blood-2012-04-424911","article-title":"Correlation of blood counts with vascular complications in essential thrombocythemia: Analysis of the prospective PT1 cohort","volume":"120","author":"Campbell","year":"2012","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1055\/s-2007-996119","article-title":"Acquired von Willebrand disease in patients with high platelet counts","volume":"23","author":"Budde","year":"1997","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1032383","DOI":"10.3389\/fphys.2022.1032383","article-title":"ADAM10: Possible functions in enamel development","volume":"13","author":"Shahid","year":"2022","journal-title":"Front. Physiol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"33714","DOI":"10.1074\/jbc.M704041200","article-title":"Hypoxia-inducible factor mediates hypoxic and tumor necrosis factor alpha-induced increases in tumor necrosis factor-alpha converting enzyme\/ADAM17 expression by synovial cells","volume":"282","author":"Charbonneau","year":"2007","journal-title":"J. Biol. Chem."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1111\/jth.12967","article-title":"Qualitative and quantitative modifications of von Willebrand factor in patients with essential thrombocythemia and controlled platelet count","volume":"13","author":"Lancellotti","year":"2015","journal-title":"J. Thromb. Haemost."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1111\/jth.15717","article-title":"Increased cleavage of von Willebrand factor by ADAMTS13 may contribute strongly to acquired von Willebrand syndrome development in patients with essential thrombocythemia","volume":"20","author":"Kubo","year":"2022","journal-title":"J. Thromb. Haemost."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Yamada, S., and Asakura, H. (2022). Coagulopathy and Fibrinolytic Pathophysiology in COVID-19 and SARS-CoV-2 Vaccination. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23063338"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s12185-023-03657-0","article-title":"Diagnostic and treatment guidelines for thrombotic thrombocytopenic purpura (TTP) in Japan 2023","volume":"118","author":"Matsumoto","year":"2023","journal-title":"Int J Hematol"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1055\/s-0038-1656329","article-title":"Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia","volume":"68","author":"Amiral","year":"1992","journal-title":"Thromb. Haemost."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1182\/blood-2013-01-477091","article-title":"Critical role for mouse marginal zone B cells in PF4\/heparin antibody production","volume":"121","author":"Zheng","year":"2013","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1182\/blood.V98.8.2442","article-title":"Heparin-induced thrombocytopenia\/thrombosis in a transgenic mouse model requires human platelet factor 4 and platelet activation through FcgammaRIIA","volume":"98","author":"Reilly","year":"2001","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood.V72.3.925.bloodjournal723925","article-title":"Heparin-induced thrombocytopenia: Laboratory studies","volume":"72","author":"Kelton","year":"1988","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1182\/blood.V98.4.1252","article-title":"Antibodies from patients with heparin-induced thrombocytopenia stimulate monocytic cells to express tissue factor and secrete interleukin-8","volume":"98","author":"Arepally","year":"2001","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1182\/blood-2013-11-539262","article-title":"Platelet transactivation by monocytes promotes thrombosis in heparin-induced thrombocytopenia","volume":"127","author":"Tutwiler","year":"2016","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1161\/ATVBAHA.120.315445","article-title":"Heparin-Induced Thrombocytopenia: A Focus on Thrombosis","volume":"41","author":"Arepally","year":"2021","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1182\/blood-2014-01-549741","article-title":"Spontaneous heparin-induced thrombocytopenia syndrome: 2 new cases and a proposal for defining this disorder","volume":"123","author":"Warkentin","year":"2014","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1111\/j.1538-7836.2010.03880.x","article-title":"Non-necrotizing heparin-induced skin lesions and the 4T\u2019s score","volume":"8","author":"Warkentin","year":"2010","journal-title":"J. Thromb. Haemost."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"4160","DOI":"10.1182\/blood-2012-07-443051","article-title":"Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: A systematic review and meta-analysis","volume":"120","author":"Cuker","year":"2012","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1182\/blood-2015-07-661215","article-title":"Diagnostic value of immunoassays for heparin-induced thrombocytopenia: A systematic review and meta-analysis","volume":"127","author":"Nagler","year":"2016","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/ajh.24006","article-title":"The platelet serotonin-release assay","volume":"90","author":"Warkentin","year":"2015","journal-title":"Am. J. Hematol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"154","DOI":"10.2152\/jmi.60.154","article-title":"Delayed-onset severe heparin-induced thrombocytopenia after total arch replacement under cardiopulmonary bypass","volume":"60","author":"Nakayama","year":"2013","journal-title":"J. Med. Investig."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e495S","DOI":"10.1378\/chest.11-2303","article-title":"Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Linkins","year":"2012","journal-title":"Chest"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1182\/bloodadvances.2018024489","article-title":"American Society of Hematology 2018 guidelines for management of venous thromboembolism: Heparin-induced thrombocytopenia","volume":"2","author":"Cuker","year":"2018","journal-title":"Blood Adv."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.accpm.2020.03.012","article-title":"Diagnosis and management of heparin-induced thrombocytopenia","volume":"39","author":"Gruel","year":"2020","journal-title":"Anaesth. Crit. Care Pain. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.chest.2017.03.050","article-title":"IVIg for Treatment of Severe Refractory Heparin-Induced Thrombocytopenia","volume":"152","author":"Padmanabhan","year":"2017","journal-title":"Chest"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1161\/01.CIR.103.14.1838","article-title":"Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia","volume":"103","author":"Lewis","year":"2001","journal-title":"Circulation"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1001\/archinte.163.15.1849","article-title":"Argatroban anticoagulation in patients with heparin-induced thrombocytopenia","volume":"163","author":"Lewis","year":"2003","journal-title":"Arch. Intern. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1182\/blood-2014-09-599498","article-title":"Fondaparinux for the treatment of suspected heparin-induced thrombocytopenia: A propensity score-matched study","volume":"125","author":"Kang","year":"2015","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1016\/j.jacc.2017.09.1099","article-title":"Use of Fondaparinux Off-Label or Approved Anticoagulants for Management of Heparin-Induced Thrombocytopenia","volume":"70","author":"Schindewolf","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1182\/blood-2014-04-571232","article-title":"Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: Evidence from phase 3 trials","volume":"124","author":"Coppens","year":"2014","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1056\/NEJM200104263441704","article-title":"Temporal aspects of heparin-induced thrombocytopenia","volume":"344","author":"Warkentin","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1055\/s-0038-1648959","article-title":"Evolution of antibodies anti-PF4\/heparin in a patient with a history of heparin-induced thrombocytopenia reexposed to heparin","volume":"72","author":"Cadroy","year":"1994","journal-title":"Thromb. Haemost."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1182\/blood-2013-10-533083","article-title":"Serological investigation of patients with a previous history of heparin-induced thrombocytopenia who are reexposed to heparin","volume":"123","author":"Warkentin","year":"2014","journal-title":"Blood"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/0140-6736(90)92558-Y","article-title":"Fatal effect of re-exposure to heparin after previous heparin-associated thrombocytopenia and thrombosis","volume":"336","author":"Gruel","year":"1990","journal-title":"Lancet"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1177\/1076029615578167","article-title":"Heparin Reexposure in Patients With a History of Heparin-Induced Thrombocytopenia","volume":"21","author":"Dhakal","year":"2015","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"c149","DOI":"10.1159\/000094960","article-title":"HIT on dialysis\u2014When is it safe to re-challenge?","volume":"104","author":"Davenport","year":"2006","journal-title":"Nephron Clin. Pract."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"c143","DOI":"10.1159\/000094959","article-title":"Pseudo-pulmonary embolism as a sign of acute heparin-induced thrombocytopenia in hemodialysis patients: Safety of resuming heparin after disappearance of HIT antibodies","volume":"104","author":"Hartman","year":"2006","journal-title":"Nephron Clin. Pract."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/j.1538-7836.2009.03734.x","article-title":"Re-exposure to heparin in uremic patients requiring hemodialysis with heparin-induced thrombocytopenia","volume":"8","author":"Wanaka","year":"2010","journal-title":"J. Thromb. Haemost."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1056\/NEJMoa2104840","article-title":"Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination","volume":"384","author":"Greinacher","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1056\/NEJMoa2104882","article-title":"Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination","volume":"384","author":"Schultz","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1056\/NEJMoa2105385","article-title":"Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination","volume":"384","author":"Scully","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1182\/blood.2021011958","article-title":"Prothrombotic immune thrombocytopenia after COVID-19 vaccination","volume":"138","author":"Tiede","year":"2021","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/ijlh.13629","article-title":"Laboratory testing for suspected COVID-19 vaccine-induced (immune) thrombotic thrombocytopenia","volume":"43","author":"Favaloro","year":"2021","journal-title":"Int. J. Lab. Hematol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.thromres.2022.03.026","article-title":"Vaccine-induced immune thrombocytopenia and thrombosis after mRNA-1273 booster vaccination","volume":"214","author":"Langerak","year":"2022","journal-title":"Thromb. Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.7326\/L21-0244","article-title":"Thrombosis With Thrombocytopenia After the Messenger RNA-1273 Vaccine","volume":"174","author":"Sangli","year":"2021","journal-title":"Ann. Intern. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"772424","DOI":"10.3389\/fmed.2021.772424","article-title":"Case Report: Vaccine-Induced Immune Thrombotic Thrombocytopenia in a Pancreatic Cancer Patient After Vaccination With Messenger RNA-1273","volume":"8","author":"Su","year":"2021","journal-title":"Front. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"E223","DOI":"10.1002\/ajh.26542","article-title":"COVID-19 mRNA-1273 vaccine induces production of vaccine-induced immune thrombotic thrombocytopenia antibodies","volume":"97","author":"Padmanabhan","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.thromres.2021.10.002","article-title":"Vaccine-induced immune thrombotic thrombocytopenia after the BNT162b2 mRNA Covid-19 vaccine: A case study","volume":"208","author":"Llamas","year":"2021","journal-title":"Thromb. Res."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Lin, T.C., Fu, P.A., Hsu, Y.T., and Chen, T.Y. (2023). Vaccine-Induced Immune Thrombotic Thrombocytopenia following BNT162b2 mRNA COVID-19 Booster: A Case Report. Vaccines, 11.","DOI":"10.3390\/vaccines11061115"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/jth.15604","article-title":"Thrombosis and thrombocytopenia after HPV vaccination","volume":"20","author":"Johansen","year":"2022","journal-title":"J. Thromb. Haemost."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s11239-021-02505-4","article-title":"Procoagulant microparticles: A possible link between vaccine-induced immune thrombocytopenia (VITT) and cerebral sinus venous thrombosis","volume":"52","author":"Marchandot","year":"2021","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1056\/NEJMoa2109908","article-title":"Clinical Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis","volume":"385","author":"Pavord","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"4053","DOI":"10.1093\/eurheartj\/ehab592","article-title":"Predictors of mortality in thrombotic thrombocytopenia after adenoviral COVID-19 vaccination: The FAPIC score","volume":"42","author":"Hwang","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/jth.15618","article-title":"Vaccine-induced immune thrombotic thrombocytopenia: Update on diagnosis and management considering different resources: Comment from Yamada et al","volume":"20","author":"Yamada","year":"2022","journal-title":"J. Thromb. Haemost."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s12185-020-03028-z","article-title":"Management of disseminated intravascular coagulation associated with aortic aneurysm and vascular malformations","volume":"113","author":"Yamada","year":"2021","journal-title":"Int. J. Hematol."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Yamada, S., and Asakura, H. (2022). Therapeutic Strategies for Disseminated Intravascular Coagulation Associated with Aortic Aneurysm. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23031296"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/2052-0492-2-20","article-title":"Classifying types of disseminated intravascular coagulation: Clinical and animal models","volume":"2","author":"Asakura","year":"2014","journal-title":"J. Intensive Care"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1016\/j.jtha.2023.09.007","article-title":"Fibrinogenolysis and fibrinolysis in vaccine-induced immune thrombocytopenia and thrombosis","volume":"21","author":"Simpson","year":"2023","journal-title":"J. Thromb. Haemost."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1182\/blood.2021012479","article-title":"The use of IV immunoglobulin in the treatment of vaccine-induced immune thrombotic thrombocytopenia","volume":"138","author":"Uzun","year":"2021","journal-title":"Blood"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1056\/NEJMoa2107051","article-title":"Adjunct Immune Globulin for Vaccine-Induced Immune Thrombotic Thrombocytopenia","volume":"385","author":"Bourguignon","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/bjh.17750","article-title":"Activation of circulating platelets in vaccine-induced thrombotic thrombocytopenia and its reversal by intravenous immunoglobulin","volume":"196","author":"McFadyen","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"10760296211048815","DOI":"10.1177\/10760296211048815","article-title":"COVID-19 Vaccine-Associated Thrombosis With Thrombocytopenia Syndrome (TTS): A Systematic Review and Post Hoc Analysis","volume":"27","author":"Hafeez","year":"2021","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1055\/a-1469-7481","article-title":"Diagnosis and Management of Vaccine-Related Thrombosis following AstraZeneca COVID-19 Vaccination: Guidance Statement from the GTH","volume":"41","author":"Oldenburg","year":"2021","journal-title":"Hamostaseologie"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s41586-021-03744-4","article-title":"Antibody epitopes in vaccine-induced immune thrombotic thrombocytopaenia","volume":"596","author":"Huynh","year":"2021","journal-title":"Nature"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/jth.15619","article-title":"Vaccine-induced immune thrombotic thrombocytopenia (VITT)\u2014Update on diagnosis and management considering different resources: Response to Comment from Yamada et al","volume":"20","author":"Greinacher","year":"2022","journal-title":"J. Thromb. Haemost."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/S2352-3026(21)00306-9","article-title":"Vaccine-induced immune thrombotic thrombocytopenia","volume":"9","author":"Klok","year":"2022","journal-title":"Lancet Haematol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.2169\/internalmedicine.8666-16","article-title":"Aortic Aneurysm-associated Disseminated Intravascular Coagulation that Responded Well to a Switch from Warfarin to Rivaroxaban","volume":"56","author":"Kadohira","year":"2017","journal-title":"Intern. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1159\/000046542","article-title":"Increased warfarin sensitivity as an early manifestation of occult prostate cancer with chronic disseminated intravascular coagulation","volume":"105","author":"Munter","year":"2001","journal-title":"Acta Haematol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1182\/blood.2021014684","article-title":"Natural history of PF4 antibodies in vaccine-induced immune thrombocytopenia and thrombosis","volume":"139","author":"Craven","year":"2022","journal-title":"Blood"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1056\/NEJMc2109465","article-title":"Therapeutic Plasma Exchange in Vaccine-Induced Immune Thrombotic Thrombocytopenia","volume":"385","author":"Patriquin","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/jca.21945","article-title":"Refractory vaccine-induced immune thrombotic thrombocytopenia (VITT) managed with delayed therapeutic plasma exchange (TPE)","volume":"37","author":"Major","year":"2022","journal-title":"J. Clin. Apher."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Panagiota, V., Dobbelstein, C., Werwitzke, S., Ganser, A., Cooper, N., Sachs, U.J., and Tiede, A. (2022). Long-Term Outcomes after Vaccine-Induced Thrombotic Thrombocytopenia. Viruses, 14.","DOI":"10.3390\/v14081702"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1055\/a-1481-3039","article-title":"Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT): Targeting Pathomechanisms with Bruton Tyrosine Kinase Inhibitors","volume":"121","author":"Lorenz","year":"2021","journal-title":"Thromb. Haemost."},{"key":"ref_76","first-page":"11","article-title":"SARS-CoV-2 vaccination associated coagulopathy","volume":"24","author":"Yamada","year":"2023","journal-title":"J. Jpn. Soc. Lab. Hematol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1172\/JCI101081","article-title":"Studies on destruction of red blood cells. II. Chronic hemolytic anemia with paroxysmal nocturnal hemoglobinuria: Certain immunological aspects of the hemolytic mechanism with special reference to serum complement","volume":"18","author":"Ham","year":"1939","journal-title":"J. Clin. Investig."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1182\/blood.V8.9.769.769","article-title":"Paroxysmal nocturnal hemoglobinuria: Relation of the clinical manifestations to underlying pathogenic mechanisms","volume":"8","author":"Crosby","year":"1953","journal-title":"Blood"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/j.1365-2141.1990.tb02546.x","article-title":"Paroxysmal nocturnal haemoglobinuria with coexisting deficiency of the ninth component of complement: Lack of massive haemolytic attack","volume":"74","author":"Yonemura","year":"1990","journal-title":"Br. J. Haematol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1001\/jama.293.13.1653","article-title":"The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: A novel mechanism of human disease","volume":"293","author":"Rother","year":"2005","journal-title":"JAMA"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/ajh.21757","article-title":"Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria","volume":"85","author":"Hillmen","year":"2010","journal-title":"Am. J. Hematol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1182\/blood.V57.1.83.83","article-title":"The kidneys in paroxysmal nocturnal hemoglobinuria","volume":"57","author":"Clark","year":"1981","journal-title":"Blood"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.1182\/blood.V93.10.3451.410k27_3451_3456","article-title":"Elevated levels of circulating procoagulant microparticles in patients with paroxysmal nocturnal hemoglobinuria and aplastic anemia","volume":"93","author":"Hugel","year":"1999","journal-title":"Blood"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s12185-010-0748-9","article-title":"Safety and efficacy of the terminal complement inhibitor eculizumab in Japanese patients with paroxysmal nocturnal hemoglobinuria: The AEGIS clinical trial","volume":"93","author":"Kanakura","year":"2011","journal-title":"Int. J. Hematol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1182\/blood-2007-06-095646","article-title":"Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria","volume":"110","author":"Hillmen","year":"2007","journal-title":"Blood"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1056\/NEJM199511093331904","article-title":"Natural history of paroxysmal nocturnal hemoglobinuria","volume":"333","author":"Hillmen","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0140-6736(95)12360-1","article-title":"Paroxysmal nocturnal haemoglobinuria: Long-term follow-up and prognostic factors. French Society of Haematology","volume":"348","author":"Mary","year":"1996","journal-title":"Lancet"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1182\/blood-2008-01-133918","article-title":"Paroxysmal nocturnal hemoglobinuria: Natural history of disease subcategories","volume":"112","author":"Mary","year":"2008","journal-title":"Blood"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"922","DOI":"10.3324\/haematol.2013.093161","article-title":"Baseline characteristics and disease burden in patients in the International Paroxysmal Nocturnal Hemoglobinuria Registry","volume":"99","author":"Schrezenmeier","year":"2014","journal-title":"Haematologica"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.cca.2010.12.011","article-title":"Haptoglobin: Old protein with new functions","volume":"412","author":"Alayash","year":"2011","journal-title":"Clin. Chim. Acta"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"3587","DOI":"10.1182\/blood-2003-01-0009","article-title":"Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria (PNH)","volume":"102","author":"Hall","year":"2003","journal-title":"Blood"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/bjh.12347","article-title":"Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria","volume":"162","author":"Hillmen","year":"2013","journal-title":"Br. J. Haematol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1111\/jth.15047","article-title":"Guidance from the Scientific and Standardization Committee for lupus anticoagulant\/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis: Update of the guidelines for lupus anticoagulant detection and interpretation","volume":"18","author":"Devreese","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1055\/s-0041-1742083","article-title":"Interaction between Antiphospholipid Antibodies and Protein C Anticoagulant Pathway: A Narrative Review","volume":"48","author":"Pengo","year":"2022","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1177\/0961203309360841","article-title":"Antiphospholipid antibodies and the protein C pathway","volume":"19","author":"Urbanus","year":"2010","journal-title":"Lupus"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1182\/bloodadvances.2018018036","article-title":"Prothrombin conversion is accelerated in the antiphospholipid syndrome and insensitive to thrombomodulin","volume":"2","author":"Kremers","year":"2018","journal-title":"Blood Adv."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1002\/art.42489","article-title":"Anti-Neutrophil Extracellular Trap Antibodies in Antiphospholipid Antibody-Positive Patients: Results From the Antiphospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking Clinical Database and Repository","volume":"75","author":"Zuo","year":"2023","journal-title":"Arthritis Rheumatol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1600-0897.1992.tb00794.x","article-title":"Antiphospholipid antibodies: Proposed mechanisms of action","volume":"28","author":"Triplett","year":"1992","journal-title":"Am. J. Reprod. Immunol."},{"key":"ref_99","first-page":"613","article-title":"Antiphospholipid syndrome in a child with trisomy 21: The relationship between anticardiolipin G antibodies and the von Willebrand factor","volume":"10","author":"Guariso","year":"1992","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1191\/096120301701548418","article-title":"Multiple thromboses in major arteries in a patient with antiphospholipid syndrome associated with excess of a large multimer of von Willebrand factor","volume":"10","author":"Mukai","year":"2001","journal-title":"Lupus"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/sj.gene.6363651","article-title":"Genetic polymorphism of murine tissue plasminogen activator associated with antiphospholipid syndrome","volume":"1","author":"Shirai","year":"1999","journal-title":"Genes. Immun."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1177\/0961203309106832","article-title":"The Euro-Phospholipid project: Epidemiology of the antiphospholipid syndrome in Europe","volume":"18","author":"Cervera","year":"2009","journal-title":"Lupus"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J. Thromb. Haemost."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1055\/s-0039-1692701","article-title":"Validity of Coagulation Activation Markers in Antiphospholipid Syndrome: A Systematic Review and Meta-analysis with a Short Data Report","volume":"45","author":"Ames","year":"2019","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s12185-022-03392-y","article-title":"Lupus anticoagulant-hypoproaccelerin (factor V) syndrome (LAHPS-V): A new hemorrhagic condition associated with lupus anticoagulant","volume":"116","author":"Ieko","year":"2022","journal-title":"Int. J. Hematol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/BOR.0000000000000932","article-title":"Antiphospholipid syndrome management: A 2023 update and practical algorithm-based approach","volume":"35","author":"Ambati","year":"2023","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.blre.2017.07.006","article-title":"Diagnosis and management of the antiphospholipid syndrome","volume":"31","author":"Chaturvedi","year":"2017","journal-title":"Blood Rev."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jacc.2022.10.008","article-title":"Direct Oral Anticoagulants vs Vitamin K Antagonists in Patients with Antiphospholipid Syndromes: Meta-Analysis of Randomized Trials","volume":"81","author":"Khairani","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1136\/annrheumdis-2019-215213","article-title":"EULAR recommendations for the management of antiphospholipid syndrome in adults","volume":"78","author":"Tektonidou","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1056\/NEJMra1312353","article-title":"Syndromes of thrombotic microangiopathy","volume":"371","author":"George","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/00005792-196603000-00003","article-title":"Thrombotic thrombocytopenic purpura: Report of 16 cases and review of the literature","volume":"45","author":"Amorosi","year":"1966","journal-title":"Medicine"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1182\/asheducation-2018.1.530","article-title":"Clinical and laboratory diagnosis of TTP: An integrated approach","volume":"2018","author":"Chiasakul","year":"2018","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1182\/blood-2017-04-636431","article-title":"Pathophysiology of thrombotic thrombocytopenic purpura","volume":"130","author":"Sadler","year":"2017","journal-title":"Blood"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/jth.13571","article-title":"Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies","volume":"15","author":"Scully","year":"2017","journal-title":"J. Thromb. Haemost."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"11902","DOI":"10.1073\/pnas.172277399","article-title":"Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity","volume":"99","author":"Kokame","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1182\/blood-2003-06-1796","article-title":"Molecular characterization of ADAMTS13 gene mutations in Japanese patients with Upshaw-Schulman syndrome","volume":"103","author":"Matsumoto","year":"2004","journal-title":"Blood"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1177\/0885066619899637","article-title":"Characteristics Behaviors of Coagulation and Fibrinolysis Markers in Acquired Thrombotic Thrombocytopenic Purpura","volume":"36","author":"Sakai","year":"2021","journal-title":"J. Intensive Care Med."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"100076","DOI":"10.1016\/j.rpth.2023.100076","article-title":"Distinguishing immune-mediated thrombotic thrombocytopenic purpura from septic disseminated intravascular coagulation using plasma levels of haptoglobin and factor XIII activity","volume":"7","author":"Yamada","year":"2023","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJM199108083250604","article-title":"Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group","volume":"325","author":"Rock","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/BF01696619","article-title":"Thrombotic thrombocytopenic purpura\/hemolytic uremic syndrome: A multivariate analysis of factors predicting the response to plasma exchange","volume":"70","author":"Pereira","year":"1995","journal-title":"Ann. Hematol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s12185-021-03197-5","article-title":"Strong association between insufficient plasma exchange and fatal outcomes in Japanese patients with immune-mediated thrombotic thrombocytopenic purpura","volume":"114","author":"Kayashima","year":"2021","journal-title":"Int. J. Hematol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s00277-009-0877-5","article-title":"High versus standard dose methylprednisolone in the acute phase of idiopathic thrombotic thrombocytopenic purpura: A randomized study","volume":"89","author":"Balduini","year":"2010","journal-title":"Ann. Hematol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1053\/j.seminhematol.2003.10.009","article-title":"The Japanese experience with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome","volume":"41","author":"Matsumoto","year":"2004","journal-title":"Semin. Hematol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1111\/trf.13182","article-title":"Poor responder to plasma exchange therapy in acquired thrombotic thrombocytopenic purpura is associated with ADAMTS13 inhibitor boosting: Visualization of an ADAMTS13 inhibitor complex and its proteolytic clearance from plasma","volume":"55","author":"Isonishi","year":"2015","journal-title":"Transfusion"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1182\/blood-2009-09-243790","article-title":"Survival and relapse in patients with thrombotic thrombocytopenic purpura","volume":"115","author":"Vesely","year":"2010","journal-title":"Blood"},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Matsumoto, M., Bennett, C.L., Isonishi, A., Qureshi, Z., Hori, Y., Hayakawa, M., Yoshida, Y., Yagi, H., and Fujimura, Y. (2012). Acquired idiopathic ADAMTS13 activity deficient thrombotic thrombocytopenic purpura in a population from Japan. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0033029"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1182\/blood-2003-01-0193","article-title":"ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: Relation to presenting features and clinical outcomes in a prospective cohort of 142 patients","volume":"102","author":"Vesely","year":"2003","journal-title":"Blood"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1182\/blood-2003-11-4035","article-title":"Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura","volume":"103","author":"Zheng","year":"2004","journal-title":"Blood"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1182\/blood-2011-03-341131","article-title":"A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura","volume":"118","author":"Scully","year":"2011","journal-title":"Blood"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/CCM.0b013e31822e9d66","article-title":"Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center","volume":"40","author":"Froissart","year":"2012","journal-title":"Crit. Care Med."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1007\/s12185-016-2019-x","article-title":"Efficacy and safety of rituximab in Japanese patients with acquired thrombotic thrombocytopenic purpura refractory to conventional therapy","volume":"104","author":"Miyakawa","year":"2016","journal-title":"Int. J. Hematol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa1806311","article-title":"Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura","volume":"380","author":"Scully","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/bloodadvances.2020001834","article-title":"Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: Integrated analysis","volume":"5","author":"Peyvandi","year":"2021","journal-title":"Blood Adv."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1007\/s12185-022-03495-6","article-title":"The efficacy and safety of caplacizumab in Japanese patients with immune-mediated thrombotic thrombocytopenic purpura: An open-label phase 2\/3 study","volume":"117","author":"Miyakawa","year":"2023","journal-title":"Int. J. Hematol."},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Saito, K., Sakai, K., Kubo, M., Azumi, H., Hamamura, A., Ochi, S., Amagase, H., Kunieda, H., Ogawa, Y., and Yagi, H. (Blood Adv., 2024). Persistent ADAMTS13 Inhibitor Delays Recovery of ADAMTS13 activity in Caplacizumab-Treated Japanese iTTP Patients, Blood Adv., Online ahead of print.","DOI":"10.1182\/bloodadvances.2023012451"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1365-2141.2012.09167.x","article-title":"Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies","volume":"158","author":"Scully","year":"2012","journal-title":"Br. J. Haematol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"E127","DOI":"10.1002\/ajh.23997","article-title":"Are platelet transfusions harmful in acquired thrombotic thrombocytopenic purpura at the acute phase? Experience of the French thrombotic microangiopathies reference center","volume":"90","author":"Benhamou","year":"2015","journal-title":"Am. J. Hematol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1111\/trf.12943","article-title":"Platelet transfusion: A systematic review of the clinical evidence","volume":"55","author":"Kumar","year":"2015","journal-title":"Transfusion"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1111\/j.1537-2995.2012.03578.x","article-title":"Splenectomy and\/or cyclophosphamide as salvage therapies in thrombotic thrombocytopenic purpura: The French TMA Reference Center experience","volume":"52","author":"Beloncle","year":"2012","journal-title":"Transfusion"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1537-2995.2005.03146.x","article-title":"Combination vincristine and plasma exchange as initial therapy in patients with thrombotic thrombocytopenic purpura: One institution\u2019s experience and review of the literature","volume":"45","author":"Ziman","year":"2005","journal-title":"Transfusion"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/ajh.21385","article-title":"Cyclosporine therapy in refractory\/relapsed patients with thrombotic thrombocytopenic purpura","volume":"84","author":"Nosari","year":"2009","journal-title":"Am. J. Hematol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/j.1365-2141.2005.05681.x","article-title":"Splenectomy for the treatment of thrombotic thrombocytopenic purpura","volume":"130","author":"Wijermans","year":"2005","journal-title":"Br. J. Haematol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.2169\/internalmedicine.52.8253","article-title":"Therapeutic modality of 11 patients with TTP in a single institution in Miyazaki from 2000 to 2011","volume":"52","author":"Kawano","year":"2013","journal-title":"Intern. Med."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1111\/jth.15010","article-title":"ISTH guidelines for treatment of thrombotic thrombocytopenic purpura","volume":"18","author":"Zheng","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1538-7836.2011.04341.x","article-title":"Natural history of Upshaw-Schulman syndrome based on ADAMTS13 gene analysis in Japan","volume":"9","author":"Fujimura","year":"2011","journal-title":"J. Thromb. Haemost."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1056\/NEJMra1813013","article-title":"Hereditary Thrombotic Thrombocytopenic Purpura","volume":"381","author":"George","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMc2210781","article-title":"Recombinant ADAMTS13 in Severe Neonatal Thrombotic Thrombocytopenic Purpura","volume":"387","author":"Stubbs","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1056\/NEJMoa2211113","article-title":"Recombinant ADAMTS13 for Hereditary Thrombotic Thrombocytopenic Purpura","volume":"387","author":"Asmis","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1182\/blood-2017-06-788026","article-title":"Recombinant ADAMTS-13: First-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura","volume":"130","author":"Scully","year":"2017","journal-title":"Blood"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/MNH.0b013e328354a62e","article-title":"Shiga toxin-associated hemolytic uremic syndrome: Advances in pathogenesis and therapeutics","volume":"21","author":"Marsden","year":"2012","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/ccr3.196","article-title":"STEC:O111-HUS complicated by acute encephalopathy in a young girl was successfully treated with a set of hemodiafiltration, steroid pulse, and soluble thrombomodulin under plasma exchange","volume":"3","author":"Yada","year":"2015","journal-title":"Clin. Case Rep."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1055\/s-0040-1713111","article-title":"Acute Myocarditis and Eculizumab Caused Severe Cholestasis in a 17-Month-Old Child Who Has Hemolytic Uremic Syndrome Associated with Shiga Toxin-Producing Escherichia coli","volume":"10","author":"Yesilbas","year":"2021","journal-title":"J. Pediatr. Intensive Care"},{"key":"ref_153","first-page":"359","article-title":"A case of Shiga toxin-producing Escherichia coli O157-assiciated hemolytic uremic syndrome lacking diarrhea or bloody stool","volume":"33","author":"Takase","year":"2021","journal-title":"J. Pediatr. Infect. Dis. Immunol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"e673","DOI":"10.1542\/peds.2004-2236","article-title":"Relative nephroprotection during Escherichia coli O157:H7 infections: Association with intravenous volume expansion","volume":"115","author":"Ake","year":"2005","journal-title":"Pediatrics"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/archpediatrics.2011.152","article-title":"Early volume expansion during diarrhea and relative nephroprotection during subsequent hemolytic uremic syndrome","volume":"165","author":"Hickey","year":"2011","journal-title":"Arch. Pediatr. Adolesc. Med."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1007\/s00467-008-1087-4","article-title":"Early erythropoietin reduced the need for red blood cell transfusion in childhood hemolytic uremic syndrome: A randomized prospective pilot trial","volume":"24","author":"Pape","year":"2009","journal-title":"Pediatr. Nephrol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1007\/s00467-010-1530-1","article-title":"Bleeding risk for surgical dialysis procedures in children with hemolytic uremic syndrome","volume":"25","author":"Weil","year":"2010","journal-title":"Pediatr. Nephrol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s10157-014-0995-9","article-title":"Guidelines for the management and investigation of hemolytic uremic syndrome","volume":"18","author":"Igarashi","year":"2014","journal-title":"Clin. Exp. Nephrol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1099\/jmm.0.001215","article-title":"Shiga toxin-producing Escherichia coli haemolytic uraemic syndrome (STEC-HUS): Diagnosis, surveillance and public-health management in England","volume":"69","author":"Jenkins","year":"2020","journal-title":"J. Med. Microbiol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"E12","DOI":"10.1542\/peds.100.1.e12","article-title":"Predictors of hemolytic uremic syndrome in children during a large outbreak of Escherichia coli O157:H7 infections","volume":"100","author":"Bell","year":"1997","journal-title":"Pediatrics"},{"key":"ref_161","first-page":"85","article-title":"A continuing assessment of risk factors for the development of Escherichia coli O157:H7-associated hemolytic uremic syndrome","volume":"42","author":"Cimolai","year":"1994","journal-title":"Clin. Nephrol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1542\/peds.90.4.616","article-title":"Risk factors for the central nervous system manifestations of gastroenteritis-associated hemolytic-uremic syndrome","volume":"90","author":"Cimolai","year":"1992","journal-title":"Pediatrics"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s10157-013-0911-8","article-title":"Diagnostic criteria for atypical hemolytic uremic syndrome proposed by the Joint Committee of the Japanese Society of Nephrology and the Japan Pediatric Society","volume":"18","author":"Sawai","year":"2014","journal-title":"Clin. Exp. Nephrol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1007\/s10157-016-1276-6","article-title":"Clinical guides for atypical hemolytic uremic syndrome in Japan","volume":"20","author":"Kato","year":"2016","journal-title":"Clin. Exp. Nephrol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJMra0902814","article-title":"Atypical hemolytic-uremic syndrome","volume":"361","author":"Noris","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1182\/blood-2007-01-070631","article-title":"Tissue factor: A link between C5a and neutrophil activation in antiphospholipid antibody induced fetal injury","volume":"110","author":"Redecha","year":"2007","journal-title":"Blood"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"3809","DOI":"10.1016\/S0021-9258(19)39666-8","article-title":"Complement proteins C5b-9 induce vesiculation of the endothelial plasma membrane and expose catalytic surface for assembly of the prothrombinase enzyme complex","volume":"265","author":"Hamilton","year":"1990","journal-title":"J. Biol. Chem."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/1750-1172-6-60","article-title":"Atypical hemolytic uremic syndrome","volume":"6","author":"Loirat","year":"2011","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1007\/s10157-018-1549-3","article-title":"Clinical characteristics and genetic backgrounds of Japanese patients with atypical hemolytic uremic syndrome","volume":"22","author":"Fujisawa","year":"2018","journal-title":"Clin. Exp. Nephrol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.2215\/CJN.02210310","article-title":"Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype","volume":"5","author":"Noris","year":"2010","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ajkd.2015.12.034","article-title":"Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial","volume":"68","author":"Fakhouri","year":"2016","journal-title":"Am. J. Kidney Dis."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.kint.2015.11.026","article-title":"Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome","volume":"89","author":"Greenbaum","year":"2016","journal-title":"Kidney Int."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/ki.2014.423","article-title":"Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies","volume":"87","author":"Licht","year":"2015","journal-title":"Kidney Int."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.kint.2020.01.035","article-title":"The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome na\u00efve to complement inhibitor treatment","volume":"97","author":"Rondeau","year":"2020","journal-title":"Kidney Int."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.kint.2020.10.046","article-title":"The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome na\u00efve to complement inhibitor treatment","volume":"100","author":"Ariceta","year":"2021","journal-title":"Kidney Int."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.kint.2016.10.005","article-title":"Atypical hemolytic uremic syndrome and C3 glomerulopathy: Conclusions from a \u201cKidney Disease: Improving Global Outcomes\u201d (KDIGO) Controversies Conference","volume":"91","author":"Goodship","year":"2017","journal-title":"Kidney Int."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.nefro.2015.07.005","article-title":"An update for atypical haemolytic uraemic syndrome: Diagnosis and treatment. A consensus document","volume":"35","author":"Campistol","year":"2015","journal-title":"Nefrologia"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00467-010-1690-z","article-title":"Pandemic H1N1 influenza A infection and (atypical) HUS--more than just another trigger?","volume":"26","author":"Allen","year":"2011","journal-title":"Pediatr. Nephrol."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1097\/INF.0b013e31828b31c8","article-title":"Trends in US hospital stays for Streptococcus pneumoniae-associated hemolytic uremic syndrome","volume":"32","author":"Veesenmeyer","year":"2013","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.molimm.2012.12.006","article-title":"Analysis of genetic and predisposing factors in Japanese patients with atypical hemolytic uremic syndrome","volume":"54","author":"Fan","year":"2013","journal-title":"Mol. Immunol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/MOP.0b013e32835d7f2c","article-title":"Update on Streptococcus pneumoniae associated hemolytic uremic syndrome","volume":"25","author":"Spinale","year":"2013","journal-title":"Curr. Opin. Pediatr."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1182\/blood-2014-11-611335","article-title":"Drug-induced thrombotic microangiopathy: A systematic review of published reports","volume":"125","author":"Reese","year":"2015","journal-title":"Blood"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/bjh.18577","article-title":"Drug-induced thrombotic thrombocytopenic purpura: A systematic review and review of European and North American pharmacovigilance data","volume":"201","author":"Schofield","year":"2023","journal-title":"Br. J. Haematol."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.transci.2018.01.003","article-title":"Cobalamin deficiency presenting with thrombotic microangiopathy (TMA) features: A systematic review","volume":"57","author":"Tran","year":"2018","journal-title":"Transfus. Apher. Sci."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12959-016-0117-x","article-title":"Proposal for new diagnostic criteria for DIC from the Japanese Society on Thrombosis and Hemostasis","volume":"14","author":"Asakura","year":"2016","journal-title":"Thromb. J."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1111\/jog.12426","article-title":"Obstetrical disseminated intravascular coagulation score","volume":"40","author":"Kobayashi","year":"2014","journal-title":"J. Obstet. Gynaecol. Res."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s12185-020-03030-5","article-title":"Diversity of disseminated intravascular coagulation and selection of appropriate treatments","volume":"113","author":"Asakura","year":"2021","journal-title":"Int. J. Hematol."},{"key":"ref_189","first-page":"265","article-title":"Criteria for diagnosis of DIC based on the analysis of clinical and laboratory findings in 345 DIC patients collected by the Research Committee on DIC in Japan","volume":"49","author":"Kobayashi","year":"1983","journal-title":"Bibl. Haematol."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1055\/s-0037-1616068","article-title":"Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation","volume":"86","author":"Taylor","year":"2001","journal-title":"Thromb. Haemost."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1097\/01.CCM.0000202209.42491.38","article-title":"A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: Comparing current criteria","volume":"34","author":"Gando","year":"2006","journal-title":"Crit. Care Med."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"196","DOI":"10.3349\/ymj.2006.47.2.196","article-title":"Plasma factor XIII activity in patients with disseminated intravascular coagulation","volume":"47","author":"Song","year":"2006","journal-title":"Yonsei Med. J."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1042\/CS20120233","article-title":"Substrates of Factor XIII-A: Roles in thrombosis and wound healing","volume":"124","author":"Richardson","year":"2013","journal-title":"Clin. Sci."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1055\/s-2007-999041","article-title":"Factor XIII deficiency: Pathogenic mechanisms and clinical significance","volume":"22","author":"Egbring","year":"1996","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1055\/s-0037-1619795","article-title":"Relevant bleeding diathesis due to acquired factor XIII deficiency","volume":"33","author":"Janning","year":"2013","journal-title":"Hamostaseologie"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/MBC.0000000000000902","article-title":"Complete hemostasis achieved by factor XIII concentrate administration in a patient with bleeding after teeth extraction as a complication of aplastic anemia and chronic disseminated intravascular coagulation","volume":"31","author":"Yamada","year":"2020","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"252","DOI":"10.3400\/avd.cr.20-00148","article-title":"Blue Rubber Bleb Nevus Syndrome Complicated by Enhanced-Fibrinolytic-Type DIC: A Case Report","volume":"14","author":"Yamada","year":"2021","journal-title":"Ann. Vasc. Dis."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1089\/jpm.2022.0249","article-title":"Effect of Anticoagulant\/Antifibrinolytic Combination Therapy on Enhanced Fibrinolytic-Type Disseminated Intravascular Coagulation in End-of-Life Stage Solid Tumor Patients","volume":"26","author":"Yamada","year":"2022","journal-title":"J. Palliat. Med."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"158","DOI":"10.7326\/L14-5014-3","article-title":"Rivaroxaban in a patient with disseminated intravascular coagulation associated with an aortic aneurysm: A case report","volume":"161","author":"Hayashi","year":"2014","journal-title":"Ann. Intern. Med."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1097\/MBC.0000000000000666","article-title":"Successful treatment with dabigatran for consumptive coagulopathy associated with extensive vascular malformations","volume":"28","author":"Yasumoto","year":"2017","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/MBC.0000000000000412","article-title":"Dabigatran etexilate versus low-molecular weight heparin to control consumptive coagulopathy secondary to diffuse venous vascular malformations","volume":"27","author":"Ardillon","year":"2016","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.thromres.2018.06.013","article-title":"Dabigatran etexilate in the treatment of localized intravascular coagulopathy associated with venous malformations","volume":"168","author":"Binet","year":"2018","journal-title":"Thromb. Res."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.jvsv.2022.09.015","article-title":"Dabigatran etexilate is efficacious in consumptive coagulopathy and pain associated with venous malformations","volume":"11","author":"Liu","year":"2023","journal-title":"J. Vasc. Surg. Venous Lymphat. Disord."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.2169\/internalmedicine.54.4942","article-title":"Use of rivaroxaban for the effective management of disseminated intravascular coagulation associated with abdominal aortic aneurysm","volume":"54","author":"Kawano","year":"2015","journal-title":"Intern. Med."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1097\/MBC.0b013e3283626238","article-title":"Management of disseminated intravascular coagulopathy with direct factor Xa inhibitor rivaroxaban in Klippel-Tr\u00e9naunay syndrome","volume":"24","author":"Randrianarisoa","year":"2013","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s11239-013-1024-7","article-title":"Rivaroxaban for the treatment of consumptive coagulopathy associated with a vascular malformation","volume":"38","author":"Vandenbriele","year":"2014","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1089\/lrb.2017.0029","article-title":"Effectiveness and Safety of Treatment with Direct Oral Anticoagulant Rivaroxaban in Patients with Slow-Flow Vascular Malformations: A Case Series","volume":"16","author":"Mack","year":"2018","journal-title":"Lymphat. Res. Biol."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1055\/s-0038-1675386","article-title":"Apixaban for the Treatment of Chronic Disseminated Intravascular Coagulation: A Report of Two Cases","volume":"39","author":"Janjetovic","year":"2019","journal-title":"Hamostaseologie"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.2169\/internalmedicine.4255-19","article-title":"Successful Treatment with Edoxaban for Disseminated Intravascular Coagulation in a Case of Aortic Dissection Complicated with Immune Thrombocytopenic Purpura","volume":"59","author":"Uemura","year":"2020","journal-title":"Intern. Med."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1182\/blood.V19.6.694.694","article-title":"Thrombotic state after a hemorrhagic diathesis, a possible complication of therapy with epsilon-aminocapproic acid","volume":"19","author":"Naeye","year":"1962","journal-title":"Blood"},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1056\/NEJM196905152802006","article-title":"Glomerular capillary thrombosis and acute renal failure after epsilon-amino caproic acid therapy","volume":"280","author":"Charytan","year":"1969","journal-title":"N. Engl. J. Med."},{"key":"ref_212","doi-asserted-by":"crossref","unstructured":"Coppo, P., Schwarzinger, M., Buffet, M., Wynckel, A., Clabault, K., Presne, C., Poullin, P., Malot, S., Vanhille, P., and Azoulay, E. (2010). Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: The French TMA reference center experience. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0010208"},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1016\/S2352-3026(17)30026-1","article-title":"Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: A cohort study","volume":"4","author":"Bendapudi","year":"2017","journal-title":"Lancet Haematol."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/trf.16188","article-title":"Reduced sensitivity of PLASMIC and French scores for the diagnosis of thrombotic thrombocytopenic purpura in older individuals","volume":"61","author":"Liu","year":"2020","journal-title":"Transfusion"},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1365-2257.2006.00755.x","article-title":"Current hematological findings in cobalamin deficiency. A study of 201 consecutive patients with documented cobalamin deficiency","volume":"28","author":"Affenberger","year":"2006","journal-title":"Clin. Lab. Haematol."},{"key":"ref_216","first-page":"77","article-title":"Disseminated intravascular coagulation (DIC). Immunohistochemical study of fibrin-related materials (FRMs) in renal tissues","volume":"37","author":"Kawasaki","year":"1987","journal-title":"Acta Pathol. Jpn."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"10760296231207629","DOI":"10.1177\/10760296231207629","article-title":"The Combination of the Lactate Dehydrogenase\/Hemoglobin Ratio with the PLASMIC Score Facilitates Differentiation of TTP from Septic DIC without Identification of Schistocytes","volume":"29","author":"Nishimura","year":"2023","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"100851","DOI":"10.1016\/j.mam.2020.100851","article-title":"Haptoglobin: From hemoglobin scavenging to human health","volume":"73","author":"Ciaccio","year":"2020","journal-title":"Mol. Aspects Med."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13054-022-04007-y","article-title":"Higher serum haptoglobin levels were associated with improved outcomes of patients with septic shock","volume":"26","author":"Lan","year":"2022","journal-title":"Crit. Care"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/9\/4956\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:38:22Z","timestamp":1760107102000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/9\/4956"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,1]]},"references-count":219,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,5]]}},"alternative-id":["ijms25094956"],"URL":"https:\/\/doi.org\/10.3390\/ijms25094956","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,1]]}}}